[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes ; day:14 ; month:12 ; year:2022 ; pages:1-13
European journal of nuclear medicine and molecular imaging ; (14.12.2022), 1-13
- Urheber
-
Santillo, Alexander F.
Leuzy, Antoine
Honer, Michael
Landqvist Waldö, Maria
Tideman, Pontus
Harper, Luke
Ohlsson, Tomas
Moes, Svenja
Giannini, Lucia
Jögi, Jonas
Groot, Colin
Ossenkoppele, Rik
Strandberg, Olof
Swieten, John van
Smith, Ruben
Hansson, Oskar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-022-06065-4
- URN
-
urn:nbn:de:101:1-2023022321014333256446
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Santillo, Alexander F.
- Leuzy, Antoine
- Honer, Michael
- Landqvist Waldö, Maria
- Tideman, Pontus
- Harper, Luke
- Ohlsson, Tomas
- Moes, Svenja
- Giannini, Lucia
- Jögi, Jonas
- Groot, Colin
- Ossenkoppele, Rik
- Strandberg, Olof
- Swieten, John van
- Smith, Ruben
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Novel insights regarding the measurement properties of the SCOPA-AUT
Fluid biomarkers in Alzheimer’s disease – current concepts
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Novel insights regarding the measurement properties of the SCOPA-AUT
Fluid biomarkers in Alzheimer’s disease – current concepts
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Novel insights regarding the measurement properties of the SCOPA-AUT
Fluid biomarkers in Alzheimer’s disease – current concepts
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies